Ascendis Pharma A/S (ASND)
NASDAQ: ASND · IEX Real-Time Price · USD
135.21
-1.31 (-0.96%)
At close: Jul 19, 2024, 4:00 PM
135.26
+0.05 (0.04%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Ascendis Pharma Employees
Ascendis Pharma had 879 employees as of December 31, 2023. The number of employees increased by 82 or 10.29% compared to the previous year.
Employees
879
Change (1Y)
82
Growth (1Y)
10.29%
Revenue / Employee
$406,864
Profits / Employee
-$620,232
Market Cap
7.65B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 879 | 82 | 10.29% |
Dec 31, 2022 | 797 | 158 | 24.73% |
Dec 31, 2021 | 639 | 157 | 32.57% |
Dec 31, 2020 | 482 | 152 | 46.06% |
Dec 31, 2019 | 330 | 114 | 52.78% |
Dec 31, 2018 | 216 | 79 | 57.66% |
Dec 31, 2017 | 137 | 36 | 35.64% |
Dec 31, 2016 | 101 | 23 | 29.49% |
Dec 31, 2015 | 78 | 23 | 41.82% |
Dec 31, 2014 | 55 | 10 | 22.22% |
Dec 31, 2013 | 45 | 7 | 18.42% |
Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
The Ensign Group | 35,300 |
Penumbra | 4,200 |
Repligen | 1,783 |
Ionis Pharmaceuticals | 927 |
Roivant Sciences | 908 |
Lantheus Holdings | 834 |
Blueprint Medicines | 655 |
Intra-Cellular Therapies | 610 |
ASND News
- 27 days ago - Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024 - GlobeNewsWire
- 6 weeks ago - Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024 - GlobeNewsWire
- 7 weeks ago - Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024 - GlobeNewsWire
- 2 months ago - FDA extends review of Ascendis Pharma's hormone disorder therapy - Reuters
- 2 months ago - Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism - GlobeNewsWire
- 2 months ago - Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial - GlobeNewsWire
- 2 months ago - Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024 - GlobeNewsWire